FDA gives Perrigo the go ahead on clobetasol propionate shampoo
The Food and Drug Administration has given its approval for the global healthcare supplier to go ahead with its new drug application said to treat psoriasis.
Perrigo's clobetasol propionate shampoo, at 0.05 percent, is intended for the treatment of moderate to severe scalp psoriasis and according to the company’s CEO Joseph C. Papa; “This is another example of our Rx team’s commitment to launching difficult to manufacture extended topical products.”
History
Back in 2009, the global healthcare supplier announced it was selling its Israel Consumer Products business for ILS205m ($44.7m) to U.S. private label cosmetics business, Emilia Group, a subsidiary of O. Feller Holdings.
Then, Papa said that for the company, the sale “reflects our on-going process of optimising our portfolio based on our stringent Return on Investment Capital (ROIC) guidelines.
